Mounjaro in Edmonton: Dual GIP/GLP-1 Therapy With Strong Weight-Loss Data
Mounjaro (tirzepatide) is the newest generation of injectable metabolic therapy in Canada — a once-weekly dual GIP and GLP-1 receptor agonist manufactured by Eli Lilly. Approved by Health Canada in November 2022, Mounjaro has produced the highest average weight loss of any approved agent in clinical trials, with SURMOUNT participants losing 15-22 percent of body weight over 72 weeks. TelePlus Care offers Edmonton-area patients same-day virtual consultations with licensed doctors who assess clinical fit, review your bloodwork, and issue a prescription you can fill at any Alberta pharmacy.
Book Your Appointment Now
A licensed doctor reviews your intake before the visit and explains the safest next step.
- Health Canada approved Mounjaro (tirzepatide) via Notice of Compliance in November 2022 for Type 2 diabetes management.
- Your intake helps the clinician understand your symptoms, history, and goals before the visit.
- Eligibility: BMI 30+ kg/m squared, or BMI 27+ with at least one weight-related comorbidity (hypertension, dyslipidemia, sleep apnea, prediabetes).
- Mechanism: dual GIP and GLP-1 receptor agonist — the only dual incretin agent in Canada; SURMOUNT-1 showed 15-22.5% body weight loss at 72 weeks.
Clinical content is reviewed for accuracy and scope. TelePlus Care appointments proceed only when clinically appropriate after a real assessment, and the doctor will explain the next step if virtual care is not the right fit.
What Is Mounjaro and How Does Dual GIP/GLP-1 Work?
Mounjaro contains tirzepatide, a single molecule that activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor — making it the only dual incretin therapy approved in Canada. GLP-1 activation slows gastric emptying, reduces appetite, and triggers meal-stimulated insulin release; GIP activation enhances insulin sensitivity and is thought to amplify the metabolic and weight-loss effects beyond GLP-1 alone. The result, in head-to-head and meta-analytic comparisons, is greater average weight loss and HbA1c reduction than semaglutide. Mounjaro is administered as a once-weekly subcutaneous injection using a single-use pre-filled pen.
Who Qualifies for Mounjaro in Edmonton?
Mounjaro's Health Canada-approved indication is Type 2 diabetes. Off-label prescribing for weight management is legal across Canada when clinically justified, and most doctors follow Obesity Canada's 2020 Clinical Practice Guidelines.
- Adults with confirmed Type 2 diabetes (HbA1c 6.5%+ or fasting glucose 7.0 mmol/L+).
- Adults with Body Mass Index of 30 kg/m squared or greater (Class I obesity).
- Adults with BMI of 27 kg/m squared or greater plus at least one weight-related comorbidity — hypertension, dyslipidemia, sleep apnea, or prediabetes.
- No personal or family history of medullary thyroid carcinoma or MEN 2 syndrome.
- No history of pancreatitis.
- Not currently pregnant or planning pregnancy within two months.
- Note: Zepbound (the weight-loss-specific tirzepatide brand) is not yet available in Canada in 2026; Mounjaro is prescribed off-label for chronic weight management.
The Virtual Consultation Process at TelePlus Care
Our Edmonton-area patients complete the assessment virtually with licensed doctors. Each prescription is documented and shared with your family doctor on request.
- Step 1: Book online — most patients secure a same-day or next-business-day appointment.
- Step 2: Complete an intake form covering medical history, BMI, comorbidities, and prior weight-loss attempts.
- Step 3: Secure video consultation (15-25 minutes) with your licensed doctor.
- Step 4: Bloodwork review or new requisition through Alberta Precision Laboratories if labs are older than 12 months.
- Step 5: Prescription issued for any Edmonton-area pharmacy. Your doctor will discuss starting dose (typically 2.5 mg) and titration schedule.
- Step 6: Structured follow-ups at 4, 12, and 24 weeks for titration and monitoring.
Required Bloodwork Before Starting Mounjaro
Standard practice requires recent metabolic and organ-function labs. Alberta Precision Laboratories collection is widely available across Edmonton.
- HbA1c — required for diabetes diagnosis or screening; baseline for monitoring.
- Fasting plasma glucose.
- Lipid profile — total cholesterol, LDL, HDL, triglycerides.
- Kidney function — eGFR and serum creatinine.
- Liver enzymes — ALT and AST.
- TSH — thyroid screening when weight changes are unexplained.
- Pregnancy test for women of reproductive age.
Access to Mounjaro in Edmonton (2026)
Mounjaro appointment steps scales with dose strength. Pens are single-use and supplied as 4 per 4-week box. details are comparable to or slightly below Wegovy at most Edmonton pharmacies.
- The booking team confirms appointment timing, intake needs, and follow-up expectations before your visit.
- Your care team confirms the visit steps, intake requirements, and follow-up plan before the appointment.
- A licensed doctor reviews your intake before the visit and explains the safest next step.
- Your intake helps the clinician understand your symptoms, history, and goals before the visit.
- Mounjaro access depends on clinical appropriateness, pharmacy availability, and your medication plan. Your pharmacist can confirm medication-specific next steps.
Side Effects of Mounjaro
Mounjaro shares the GLP-1 side-effect profile, with most events appearing during titration and resolving within 8-12 weeks. The dual-receptor mechanism does not appear to introduce categorically new safety concerns relative to semaglutide.
- Nausea — most common; affects 25-35% during titration.
- Diarrhea or constipation.
- Vomiting, particularly during dose increases.
- Decreased appetite — usually desired but can be pronounced.
- Injection site reactions.
- Hypoglycemia risk in patients on insulin or sulfonylureas.
- Rare: pancreatitis — severe abdominal pain radiating to the back; seek urgent care.
- Rare: gallbladder problems including gallstones.
- Rare: acute kidney injury secondary to dehydration.
Mounjaro Compared to Wegovy, Ozempic, and Saxenda
Mounjaro consistently outperforms semaglutide on average weight loss in clinical trials, but clinical fit and pharmacy availability are the deciding factors for many patients.
- Mounjaro (tirzepatide, weekly) — ~15.0-22.5% body weight loss at 72 weeks (SURMOUNT-1). Highest efficacy in head-to-head data.
- Wegovy (semaglutide 2.4 mg, weekly) — ~14.9% at 68 weeks. On-label for weight loss but supply intermittent.
- Ozempic (semaglutide 2.0 mg, weekly) — ~12-15%, off-label for weight loss, reliable supply.
- Saxenda (liraglutide 3.0 mg, daily) — ~8.0% at 56 weeks, decade of safety data, may be more readily available.
- Mounjaro may be preferred when efficacy is the priority and access is clinically appropriate; Ozempic may be preferred when supply or access favours semaglutide.
Why Choose TelePlus Care for Mounjaro in Edmonton
TelePlus Care offers Edmonton-area adults timely, evidence-based access to all Health Canada-approved metabolic therapies — including the newest dual incretin agent. Our doctors are licensed in Alberta and follow Obesity Canada and Diabetes Canada guidelines. We don't dispense medication — we issue prescriptions you fill at any Edmonton-area pharmacy. Same-day virtual visits, clear appointment steps, secure digital lab requisitions, and structured follow-ups are standard. If Mounjaro is the right molecule for you, we can usually have you started within 24-48 hours.
Your Fast and Convenient Healthcare Solution
Connect with a licensed healthcare provider from the comfort of your home. No referral needed — book your virtual appointment today.
Book Your Appointment Now
Other Alberta Locations
We also provide this service in these Alberta communities:
Teleplus care clinic is not an urgent care clinic. If you have an emergency please call911 or go to the nearest urgent care facility.
